March 31, 2016
Santen Pharmaceutical has earned exclusive worldwide rights to manufacture, develop, and commercialize Ono Pharmaceutical’s ONO-9054, an FP and EP3 dual receptor agonist, which is being developed as a treatment of glaucoma and ocular hypertension. The two companies said on March...read more